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131.	 Department	of	Immunology,	Rheumatology	and	Allergy,	Medical	University	of	Lodz,	and	HARC,	Poland		203	
132.	 University	of	Groningen,	University	Medical	Center	Groningen,	Beatrix	Children’s	Hospital,	Department	of	Pediatric	Pulmonology	204	
and	Pediatric	Allergology,		GRIACResearch	Institute,		,	Groningen,	the	Netherlands		205	
133.	 Division	of	Internal	Medicine,	Asthma	and	Allergy,	Barlicki	University	Hospital,	Medical	University	of	Lodz,	Poland		206	
134.	 Clinic	of	infectious,	chest	diseases,	dermatology	and	allergology,		Vilnius	University,	Vilnius,	Lithuania		207	
135.	 AReS	Puglia,	Bari,	Italy		208	
136.	 The	Queen's	Medical	Research	Institute,	University	of	Edinburgh,	UK	209	
137.	 University	of	Nantes,	Service	de	Pneumologie,	UMR	INSERM,	UMR1087and	CNR	6291,	l'institut	du	thorax,	Nantes,	France		210	
138.	 Department	of	Respiratory	Medicine,	University	of	Bratislava,	Bratislava,	Slovakia		211	
139.	 Department	of	Medicine	(RCSI),	Bon	Secours	Hospital,	Glasnevin,	Dublin,	Ireland		212	
140.	 TicSalut,	Departament	de	Salut		|,		Generalitat	de	Catalunya,	Mataró,	Spain		213	
141.	 Institute	of	Environmental	Medicine,	Karolinska	Institutet,	Stockholm		214	
142.	 Croatian	Pulmonary	Society		215	
143.	 National	Institute	of	Pneumology	M.	Nasta,	Bucharest,	Romania		216	
144.	 Faculty	of	Medicine,	University	of	Belgrade,	Belgrade,	Serbia.	Serbian	Association	for	Asthma	and	COPD	217	
145.	 Department	of	Public	health	and	biostatistics,	Paris	Descartes	University,	EA	4064		218	
146.	 Paris	municipal	Department	of	social	action,	childhood,	and	health,	Paris,	France		219	
147.	 Lead	Respiratory	Physician	Mater	Dei	Hospital	Malta,	Academic	Head	of	Dept	and	Professor	of	Medicine	University	of	Malta,	220	
Deputy	Dean	Faculty	of	Medicine	and	Surgery	University	of	Medicine,	La	Valette,	Malta		221	
148.	 Immunoallergy.		222	
149.	 SPAIC.		223	
150.	 Institute	of	Medical	Statistics,	Informatics	and	Epidemiology,	Medical	Faculty,	University	of	Cologne,	Germany		224	
151.	 Rhinology.		225	
152.	 Department	of	Immunology	and	Allergology,	Faculty	of	Medicine	and	Faculty	Hospital	in	Pilsen,	Charles	University	in	Prague,	226	
Pilsen,	Czech	Republic		227	
153.	 Center	for	Pediatrics	and	Child	Health,	Institute	of	Human	Development,	Royal	Manchester	Children's	Hospital,	University	of	228	
Manchester,	Manchester	M13	9WL,	UK.	Allergy	Department,	2nd	Pediatric	Clinic,	Athens	General	Children's	Hospital	"P&A	229	
Kyriakou,"	University	of	Athens,	Athens	11527,	Greece.		230	
154.	 Allergy.		231	
155.	 Children’s	Hospital	Srebrnjak,	Zagreb,	School	of	Medicine,	University	J.J.	Strossmayer,	Osijek,	Croatia	232	
156.	 Clinic.		233	
157.	 University	of	Groningen,	University	Medical	Center	Groningen,	Department	of	Pulmonary	Medicine	and	Tuberculosis,	GRIAC	234	
Research	institute,	Groningen,	the	Netherlands		235	
158.	 Optimum	Patient	Care,	Cambridge	and	Academic	Centre	of	Primary	Care,	University	of	Aberdeen,	Aberdeen,	UK.		236	
159.	 Pneumologie	et	Soins	Intensifs	Respiratoires,	Hôpitaux	Universitaires	Paris,	Centre	Hôpital	Cochin,	France		237	
160.	 Allergy	Unit,	Complesso	integrato	Columbus,	Rome,	Italy.		238	
161.	 Serviço	de	Imunoalergologia.	Hospital	da	Luz.	Lisboa.	Portugal.		239	
162.	 General	Practitioner,	Woodbrook	Medical	Centre,	Loughborough,	UK;	Honorary	Clinical	Research	Fellow,	Allergy	and	Respiratory	240	
Research	Group,	The	University	of	Edinburgh,	Edinburgh,	UK.		241	
163.	 Otolaryngology	and	Head	&	Neck	Surgery,	CHU	Rangueil-Larrey,	Toulouse,	France,		242	
164.	 Allergy	Unit,	Department	of	Dermatology,	University	Hospital	of	Zurich,	Zürich,	Switzerland		243	
165.	 Allergy	and	Respiratory	Research	Group,	Centre	for	Population	Health	Sciences,	The	University	of	Edinburgh,	Medical	School,		244	
166.	 Child.		245	
167.	 Department	of	Thoracic	Medicine,	University	Hospital	of	Heraklion,	Crete,	Greece		246	
168.	 DIBIMIS,	University	of	Palermo,	Italy		247	
169.	 Department	of	Otorhinolaryngology,	Akershun	University	Hospital,	Nordbyhagen,	Oslo		248	
170.	 Julius	Center	of	Health	Sciences	and	Primary	Care,	University	Medical	Center	Utrecht,	University	of	Utrecht,	Utrecht,	the	249	
Netherlands		250	
171.	 Global	Allergy	and	Asthma	Platform	GAAPP,	Altgasse	8-10,	1130	Vienna,	Austria		251	
172.	 Kyrgyzstan	National	Centre	of	Cardiology	and	Internal	medicine,	Euro-Asian	respiratory	Society,	Bishkek,	Kyrgyzstan		252	
173.	 Academic	Medical	Centre,	University	of	Amsterdam,	The	Netherlands.		253	
174.	 Centre	of	Pneumology,	Faculty	of	Medicine,	University	of	Coimbra,	Coimbra,	Portugal.		254	
175.	 Pneumology	and	Allergy	Department.	Hospital	Clínic,	Clinical	&	Experimental	Respiratory	Immunoallergy,	IDIBAPS,	Barcelona,	255	
Spain.	256	
176.	 Dept.	of	Lung	Diseases	and	Clinical	Allergology,	University	of	Turku,	Finland.		257	
177.	 Unité	de	Pharmacoépidémiologie,	CHU-Lyon	-	UR	5558	CNRS	-	Université	Claude	Bernard	Lyon,	France.		258	
178.	 Clinical	Immunology	and	Allergy	Unit,	Department	of	Medicine	Solna,	Karolinska	Institutet	and	University	Hospital,	Stockholm		259	
179.	 University	of	Bari	Medical	School,	Unit	of	Geriatric	Immunoallergology,	Bari,	Italy		260	
180.	 Dept	of	Otorhinolaryngology,	HNO-Klinik,	Universitätsklinikum	Düsseldorf,	Germany		261	
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181.	 Cyprus	International	Institute	for	Environmental	&	Public	Health	in	Association	with	Harvard	School	of	Public	Health,	Cyprus	262	
University	of	Technology,	Limassol,	Cyprus;	Department	of	Pediatrics,	Hospital	"Archbishop	Makarios	III",	Nicosia,	Cyprus.		263	
182.	 Social	Sciences,	University	of	Southampton		264	
183.	 University	Clinic	of	Respiratory	and	Allergic	Diseases,	Golnik,	Slovenia.		265	
184.	 Funka,	Sweden		266	
185.	 Project	Officer,	EC-CNECT-H2,	European	Commission,	Brussels,	Belgium		267	 	268	
	269	
	270	
	271	
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Summary	273	
The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy 274	
Ageing (EIP on AHA) has proposed six Action Groups. After almost three years of activity, many 275	
achievements have been obtained through commitments or collaborative work of the Action 276	
Groups. However, they have often worked in silos and consequently synergies between Action 277	
Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the 278	
methodology and current status of the Task Force on EIP on AHA synergies.  Synergies are in line 279	
with the Action Groups’ new Renovated Action Plan (2016-2018) to ensure that their future 280	
objectives are coherent and fully connected. Outcomes and impact of synergies are using the 281	
Monitoring and Assessment Framework for the EIP on AHA (MAFEIP). Eight proposals for 282	
synergies have been approved by the Task Force: Five Cross-cutting synergies which can be used 283	
for all current and future synergies as they consider overarching domains (appropriate 284	
polypharmacy, citizen empowerment, teaching and coaching on AHA, deployment of synergies to 285	
EU regions, Responsible Research and Innovation), and three cross-cutting synergies focussing on 286	
current Action Group activities (falls, frailty, integrated care and chronic respiratory diseases). 287	
	288	
	289	
Abbreviations	290	
 291	
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CoP: Conference of Partners 294	
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Introduction	316	
The European Commission aims to enhance European competitiveness and tackle societal 317	
challenges through research and innovation (European Innovation Partnerships (EIP)). Active and 318	
Healthy Ageing (AHA) is a major health and societal challenge in all European countries, and an 319	
area with considerable potential for European leadership. Therefore an initiative was launched by 320	
the EIP on AHA to accomplish a triple win (1): 321	
• Enabling citizens to lead healthy, active and independent lives while ageing. 322	
• Improving the sustainability and efficiency of social and health care systems. 323	
• Boosting and improving the competitiveness of the markets for innovative products and services 324	
responding to the ageing challenge. 325	
The EIP on AHA programme framework defined priority areas of work translated into six specific 326	
Action Groups (AG) (Table 1). 327	
Table	1:	Action	groups	of	the	EIP	AHA	(1)	328	
• Prevention	of	diseases	and	health	promotion	329	
o Finding	 innovative	ways	 to	 ensure	 that	 patients	 follow	 their	 prescriptions	 and	 treatments	once	 treatments	 are	330	
optimised	to	ensure	appropriate	polypharmacy	that	optimised	outcomes	from	medicines	whilst	minimising	harm.	331	
(Action	Group	A1).	332	
o Finding	innovative	solutions	to	better	manage	our	own	health	and	to	prevent	falls	(Action	Group	A2).	333	
o Helping	to	prevent	functional	decline	and	frailty,	with	a	particular	focus	on	malnutrition	(Action	Group	A3).	334	
• Care	 and	 cure:	 Promoting	 integrated	care	models	 for	chronic	diseases,	 including	 the	use	of	 remote	monitoring	335	
(Action	Group	B3).		336	
• Active	and	independent	living	of	older	adults:	Developing	ICT	solutions	to	help	people	stay	independent	and	337	
more	active	for	longer	(Action	Group	C2).	338	
• Horizontal	 topics:	 horizontal	 axis	 of	 transversal,	 framework	 and	 supportive	 topics,	 of	 which	 age-friendly	339	
environments	(Action	Group	D4).	340	 	341	
Over 500 commitments were submitted from organisations (Table 2) and 32 Reference Sites were 342	
recognised in July 2013 as excellence sites for innovation in AHA.  343	
 344	
Table	2:	Terminology	used	in	the	paper	345	
 346	
Organisations	can	participate	in	the	EIP	on	AHA	using:	347	
• Individual	commitments:	Individual	task	of	an	AG.	348	
• Collaborative	work:	Project	agreed	by	an	AG	and	carried	out	by	several	organisations.			349	
Results	 are	 tangible	 outcomes	 from	 commitments	 and/or	 collaborative	work	 (e.g.	 a	 report,	 a	 completed	350	
pilot	study,	a	guideline,	etc.).	They	have	to	be	specific,	measurable,	achievable	and	time-bound.		351	
Synergies	 (defined	by	 the	Synergy	TF	 in	coordination	with	AGs):	Commitments	and/or	collaborative	work	352	
with	cross-cutting	interest	and	relevance	to	several	AGs.	They	were	established	using	a	concerted	approach.	353	
A	synergy	should	be	in	line	with	the	individual	AG’s	Renovated	Action	Plan.		354	
Collaborative	work	and	Synergies	can	be	managed	on	a	voluntary	basis	following	the	objectives	set	or	in	a	355	
more	agile	way	using	SPRINTS	that	are	proposed	using	a	specific	template	with	defined	short-term	results	356	
reported	every	6	months.	 	 In	software	product	development,	a	sprint	 is	a	set	period	of	time	during	which	357	
specific	work	has	to	be	completed	(http://searchsoftwarequality.techtarget.com/definition/Scrum-sprint).	358	
1-	Aim	of	the	Task	Force	on	synergies	359	
The EIP on AHA requires a multidimensional and multidisciplinary approach to allow people from 360	
multiple backgrounds to work together sharing a common language. After three years of 361	
collaboration and activities, many achievements were obtained by the six AGs. However, they have 362	
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often worked in silos. Now that AGs have matured, more attention can be given to collaboration 363	
across AGs for topics with a shared interest.  364	
In the next phase of the EIP on AHA programme, synergies will be initiated for a practical, action-365	
oriented contribution to a common framework that will be used to further strengthen the triple win 366	
of the EIP on AHA.    367	
More specifically, the aims of the TF are to: 368	
1- Outline the methodology and current status of the EIP on AHA synergies.   369	
2- Align with the AG Renovated Action Plan (RAP) to ensure that RAP and synergies are 370	
coherent and fully connected. 371	
3- Evaluate the progress, results and impacts of the synergies with MAFEIP (Monitoring and 372	
Assessment Framework for the EIP on AHA) (2, 3). 373	
4- Support the existing EIP on AHA Scaling Up Strategy (https://ec.europa.eu/research/innovation-374	
union/pdf/active-healthy-ageing/scaling_up_strategy.pdf) 375	
2-	Methodology	used	by	the	Task	Force	to	develop	synergies	376	
The Synergy Task Force (TF) was initiated November 4, 2015 in order to develop concrete actions 377	
to be presented during the 2015 EIP on AHA Conference of Partners (December 9-10, 2015). A 378	
transparent methodology has been developed and all AGs were asked to propose at least one 379	
synergy. Nine proposals have been submitted and eight were accepted by the TF after applying the 380	
pre-defined quality criteria. A meeting in Montpellier (MACVIA-7) held two days before the AHA 381	
Conference of Partners helped to fine tune the synergy proposals and suggest a plan for future 382	
actions (Nogues, in preparation). 383	
2-1-	Selection	of	task	force	members	384	
A TF was set up to identify synergies, describe and evaluate them. Initially, each AG selected at 385	
least 2 members but, as the process was flexible, some AG proposed up to 7 members. Members of 386	
PROEIPAHA Coordination and Support Action and the AG promoters were also invited to 387	
participate in the TF. All the TF members are authors of this paper. 388	
2-2-	Template	to	develop	proposals	for	synergies	389	
Synergies were based on a common 4-page template that was unanimously agreed by all the TF 390	
members (Table 3).   391	
Table	3:	Template	used	to	submit	synergies	392	
1. Title	of	the	proposal	393	
2. Leading	organisation	394	
3. Supporting	organisations	395	
4. Action	groups	396	
	 A1	 A2	 A3	 B3	 C2	 D4	
AG	initiating	the	proposal	 	 	 	 	 	 	
AG	already	involved	 	 	 	 	 	 	
AG	to	be	contacted	 	 	 	 	 	 	
5. Rationale	for	the	synergy	397	
6. Achievements	of	the	EIP	on	AHA	AG	398	
7. Objectives	399	
• General	objectives	400	
• Specific	objectives	401	
8. Concrete	plan	402	
9. SPRINTS	(2016-2017)	403	
N°	 Name	 AG	 Starting	date	 Delivery	date	 Geographical	
distribution	
Results	
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S1	 	 	 	 	 	 	
S2	 	 	 	 	 	 	
10. Associated	EU	programmes	404	
11. Alignment	with	the	EIP	on	AHA	objectives	405	
12. Resources	currently	available	for	the	projects	406	
13. Expected	impact	407	
2-3-	Assessment	of	proposals	408	
A transparent methodology has been developed to evaluate the synergies on relevance, quality and 409	
applicability. Templates were evaluated by two members of each AG based on a set of criteria 410	
checked through Survey Monkey (Figure 1) (www.surveymonkey.com). All proposals with a 411	
threshold mean level of 6/10 or above for all the 9 criteria were approved (unanimous decision was 412	
required). The inter-rater variance was low between assessments. Proposals that did not reach the 413	
threshold level were revised and further approved. Finally, 8 proposals were accepted and one was 414	
withdrawn. 415	
Figure	1:	Survey	Monkey	evaluation	of	proposed	synergies	416	
	417	
2-4-	Type	of	synergies	418	
Two types of complementary cross-cutting synergies were submitted (Figure 2):  419	
• Synergies considered overarching as they address topics that are relevant for most or all AGs 420	
• Cross-cutting synergies focussing on a current AG activity which will be deployed to other 421	
AGs  422	
	423	
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Figure	2:	Synergies	of	the	EIP	on	AHA			424	
	 	425	
Six synergies (adherence in medical plans, masters of AHA, RRI, Falls prevention, Frailty and 426	
CRDs) had a clear plan with milestones and defined results. Short-term activities for these 427	
synergies can be defined using the SPRINT methodology. The other two  should be considered as 428	
collaborative work. 429	
The 8 synergies are detailed in the online supplement. 430	
3-	Proposed	Synergies	activities	431	
3-1-	Overarching	synergies		432	
3-1-1-	Information	technology	and	adherence	in	ageing	population	with	chronic		433	
diseases	and	appropriate	polypharmacy	434	
H	Papadopoulos,	D.	Pappa,	P	Kardas,	A	Mair,	A	Monaco,	Z	Gutter			435	
Leading	AG:	A1	436	
Rationale: Multimorbidity of chronic and acute diseases leads to the use of multiple medications 437	
(polypharmacy), increasing the risk of drug interactions, poor adherence to treatment and adverse 438	
drug reactions (ADR). Failure to adhere to medical treatment, especially for old age people 439	
increases therapeutic failure (4), causes unnecessary complications (5) and increases hospitalization 440	
and healthcare costs (6).   441	
General	 objectives: To increase the adherence to treatment of older age adults with chronic 442	
diseases and polypharmacy (i) assessing the role of ICT - based solutions such as advanced 443	
processing of data, decision support applications and remote monitoring and consultation systems, 444	
and (ii) implementing tailored ICT- based interventions 445	
Specific	objectives		446	
1- To study if application of progressive ICT systems that connect patient with health care 447	
professionals can boost adherence at seniors in long-term therapies and polypharmacy. The role 448	
of pharmacists will also be considered. Results from a running pilots in EU countries will be 449	
used for deployment.   450	
2- To study the role of integrated information systems connecting all stakeholders (e.g. patients, 451	
family members, health and social carers, and members of municipalities, hospitals, social care 452	
entities). Results from a running pilots in Europe will be used for deployment. 453	
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3- To review best practices and available literature to assess whether ICT - based applications that 454	
support training, patient empowerment and social interactions can change behaviour and 455	
increase adherence of older age adults to treatment. 456	
4- Use the lessons learnt in Italy by a National plan for Adherence involved The Italian Medicines 457	
Agency (AIFA), the national federation of general practitionners (FIMMG), Geriatrics and 458	
Patients association (in particular Federanziani) and universities. The barriers and results of this 459	
network can be used to develop or scale up innovative approaches at the EU level. 460	
Contribution	to	the	Scaling	Up	Strategy	of	the	EIP	on	AHA:	How	many	regions The study intends 461	
to exploit results from many EU countries.  	462	
Expected	Outcomes	/	Contribution	to	MAFEIP	463	
1- Impact on QOL: Increased adherence of elderly people to medical plans will promote healthier 464	
ageing and their QOL. Adherence to prescribed treatment and improved disease development 465	
will reduce complications  466	
2- Impact on Sustainability of Health and Care Systems: Increased adherence to medical plans 467	
impacts sustainability of the healthcare systems. Specific metrics used in the study is in process 468	
to be defined. 469	
3- Impact on Economic, Growth and Jobs for both the pharmaceutical industry and in the area of 470	
home care technologies and services. Opportunities for  new advanced products development 471	
and production are expected to be generated and also more qualified jobs will be required for 472	
the new services.       473	
3-1-2-	Citizen	and	patient	empowerment	474	
C	Vera-Muñoz,	D	Somekh,	F	Avolio,	N	Guldemond,	G	Fico	475	
Leading	AG:	B3,	Action	Area	6	476	
Rationale: Nearly all the Action Plans launched in 2012 refer to patient or citizen empowerment. 477	
Citizen and patient empowerment is a growing interest policy area.  Active involvement of patients 478	
in their interaction with health and social professionals increases care effectiveness and efficiency. 479	
Citizen empowerment and the facilitating role of ICT are key topics in the EU H2020 programme. 480	
However, the work done in the EIP on AHA showed divergent understanding of citizen 481	
empowerment: defined in terms of education, joint decision-making and self-management. Tools 482	
such as measures of health literacy and the capacity of individuals or groups for self-management 483	
in chronic conditions would be of considerable value in reducing social inequalities.	484	
General	objectives:	To achieve a common understanding of citizen and patient empowerment, and 485	
to implement and scale-up good practices.		486	
Specific	objectives	487	
1- Develop a consensus view of citizen and patient empowerment across the different AGs. 488	
2- Share and align citizen empowerment related activities within and across AGs. 489	
3- Formulate a set of broad holistic actions, based on a common understanding, to facilitate the 490	
scaling-up of good and effective practices via transverse (Synergies TF) as well as vertical 491	
processes (AGs) that support the overall objectives of the EIP on AHA. 492	
4- Scale-up good practices and disseminate of knowledge via the Synergies TF, the AGs, the 493	
Reference Sites and relevant EU and national initiatives. 494	
Contribution	to	the	Scaling	Up	Strategy	of	the	EIP	on	AHA:	How	many	regions	495	
All EIP on AHA partners and regions will be involved in this synergy. Additionally, all Reference 496	
Sites in the Reference Site Collaborative Network (RSCN) will be invited to participate.  497	
Expected	 Outcomes	 /	 Contribution	 to	 MAFEIP:	 “Patients with chronic conditions are often 498	
referred to as the most under-used resource in the health system while patient-centred care models 499	
have demonstrated better quality of care as well as potential long-term cost-efficiencies. Too many 500	
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patients are still struggling to get the support they need to become equal partners in care. To make 501	
real progress, we need to make patient empowerment a priority, starting with the development of 502	
an EU-wide strategy and action plan”1	503	
1. Impact on QOL with an adequate social network and sufficient empowerment (7-10). 504	
2. Impact on Sustainability of Health and Care Systems: Empowerment of patients and citizens is 505	
seen as a key aspect of maintain health and care systems sustainable (11, 12).. 506	
3. Impact on Economic, Growth and Jobs: Empowered citizens are more self-sustaining and 507	
economically productive (13, 14). 	508	
3-1-3-	Masters	of	AHA’	educating	seniors,	health	and	social	carers	and	entrepreneurs		509	
N	Goswami,	A	Nizinska,	R	Roller-Wirnsberger,	P	Eklund,	J	Malva,	C	Jeandel,		H	Blain,	M	Nogues	510	
Leading	AG:	A2	511	
Rationale: Integrated, interdisciplinary and inter-professional education for all stakeholders is 512	
needed to tackle the interrelated syndrome of frailty, malnutrition, falls, chronic diseases, and their 513	
social consequences. 	514	
General	objectives:	Development of an innovative, dynamic and sustainable care system for AHA 515	
by capacity building through senior/patient centred, multidisciplinary and inter-professional 516	
educational programmes	 aimed at patients, patient caregivers (both formal and informal), health 517	
and social carers, administrators and entrepreneurs. 	518	
Specific	objectives:	519	
1- Multi-professional education to improve the links between all stakeholders through better 520	
understanding of the knowledge and competencies of each stakeholder. 521	
2- Master of Gerontology and Geriatrics: To develop dynamic and sustainable care systems that 522	
will encompass inter-disciplinary, inter-professional education (IPE) and learning (IPL) 523	
including RRI business models.   524	
3- Best evidence holistic perspective to bring together research, practice, policies and market by 525	
courses in medical, nursing, pharmacy, social, behavioural, psychological, economic 526	
physiological, management service aspects related to prevention and management of ageing and 527	
using the innovation loop of planning up-scaling strategies.  528	
4- To promote AHA as well as the empowerment of self-care and (care) independency, by placing 529	
the older person at the centre of care.   530	
Contribution	 to	 the	Scaling	Up	Strategy	of	 the	EIP	on	AHA:	The program will be started at the 531	
Medical University of Graz, Austria by a well-defined Master of Gerontology and Geriatrics in 532	
English. The course teachers and participants will be from different institutions in Europe. This 533	
programme will be a pilot for other European programmes. The multi- professional approach will 534	
be developed in collaboration with the European Interdisciplinary Council on Aging (EICA) 535	
gathering professionals from all disciplines interested in AHA also implementing knowledge 536	
transfer to political, economic and lay stakeholders in the field. 537	
Regions	to	be	included:	Regions will have a role for both of contributors, sharing their experiences 538	
and best practices as well as learners, willing to implement and improve existing state of the art in 539	
educating all level stakeholders in AHA. State-of-the-art running programmes will also contribute 540	
to this synergy.	Some examples of education programmes carried out in other regions are given in 541	
Table 4. 542	
Table	4:	Examples	of	Masters	of	Gerontology	and	Geriatrics	in	Europe	543	
 544	
Country	 Region	or	
Reference	site	
Website	 Title	 Language	
																																																								1	EPF	President,	Anders	Olauson	
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Austria	 Graz	Medical	
University	
	 Master	of	Gerontology	and	
Geriatrics	
English	
Austria	 Medical	Doctors’	
Association	
Austria	
http://www.aerztekammer.a
t/veranstaltungen	
Postgraduate	Training	Course	for	
Medical	Doctors	in	Geriatric	
Medicine		
German	
Belgium	 European	
Academy	of	
Aging	(EAMA)	
	
http://eama.eu	 Leadership	programme	for	
academic	geriatricians	
English	
France	 Languedoc	
Roussillon	(15-
17)	
http://reseau-idefi-
2015.strikingly.com	
Trans	Innov	Longévité:	Trans-
disciplinary,	multisectoral,	
private-public	partnership	to	
train	and	coach	on	frailty,	ageing	
and	independent	living		
French	
Portugal	 Ageing@Coimbra	 http://www.ed.uc.pt/educ/curs
o?id=96	
Distance	Learning	Course	for	
Care	Providers	and	the	general	
public	
Portuguese	
UK	 British	Geriatric	
Society		
http://www.bgs.org	 Spring	Postgraduate	training	
course	geriatric	medicine	
Edinburgh	Scotland		
English	
UK	 University	of	
Oxford	
http://www.oxford.edu.	 Onsite	training	courses		 English	
To	ensure	efficient	running	of	the	programme: A scientific advisory committee has been put in 545	
place to elaborate a landscape of educational events taht will be retrieved from the homepage of the 546	
Medical University of Graz/Austria. Experts on the committee will set up quality standards for live 547	
as well as long distance educational events in the field of AHA (e-learning). Experts will be chosen 548	
by the committee for their educational, clinical and/or research expertise in the field of AHA. The 549	
committee will be composed of members from all stakeholders involved in AHA across Europe. 550	
The committee will work closely with the members of the RRI framework to ensure evidence 551	
based multi-professional education and to deliver educational research results per se.			552	
Expected	Outcomes	/	Contribution	to	MAFEIP	553	
1-  Impact on QOL of seniors 554	
2- Ensure health promotion, literacy, engagement and empowerment of senior citizens in aspects 555	
related to adopting interventions and life styles that promote active and health aging (e.g. 556	
acceptance of evidence based interventions, behavioural changes towards AHA). 557	
3- Impact on Sustainability of Health and Care Systems 558	
4- Impact on Economic, Growth and Jobs 559	
3-1-4-	AHA	in	the	framework	of	Responsible	Research	and	Innovation	(RRI)	560	
I	Monsonís-Paya,	M	Hinkema,	J	Martin,	AS	Parent,	J	García,	M	Ferri	561	
Leading	AG:	D4	562	
Rationale: Responsible Research and Innovation (RRI) is an approach that anticipates and assesses 563	
potential implications and societal expectations of research and innovation (18, 19). RRI allows all 564	
stakeholders involved in research and innovation (i) to obtain relevant knowledge on the 565	
consequences of the outcomes of their actions, (ii) to effectively evaluate outcomes in terms of 566	
societal needs and moral values and (iii) to use these considerations for design and development of 567	
new research, products and services (18). The concept in Europe considers eight key areas (20) that 568	
should be included in the dialogue among the different AGs of the EIP AHA such as Governance, 569	
Public Engagement, Gender Equality, Science Education, Open Science/Open access, Ethics, 570	
Sustainability and Social Justice/Inclusion. 571	
General	objectives: To provide a roadmap of actions to be undertaken to promote RRI in AHA. 572	
Specific	objectives:	573	
1- To identify the current state of the actions and initiatives related to the concept of RRI in the 574	
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AHA framework and the concrete contribution of the partners and AGs. . 575	
2- To create a group of partners interested in working in this area and identifying the most urgent 576	
actions and the plan of execution on RRI in AHA for the following years.  577	
3- To analyse the work done in AHA in terms of RRI in the framework of the EIP AHA and other 578	
related networks. 579	
4- To provide a roadmap of urgent action to be undertaken on RRI on AHA. 580	
Contribution	to	the	Scaling	Up	Strategy	of	the	EIP	on	AHA:	The synergy considers the engagement 581	
of higher number and more diverse stakeholders involved in the chain supply of active and healthy 582	
ageing products and services, including grass-root stakeholders (at local and regional level) with no 583	
possibility to join the EIP AHA in Brussels due to economic, linguistic or time limitations in order 584	
to promote a richer dialogue and collaboration. To this regard, the D4 partners/coordinators 585	
initially suggested to consider new agents as actors participating in the promotion of active and 586	
healthy ageing at early stages and other actors supporting innovative ways of promoting active and 587	
healthy ageing elderly people i.e. schools, volunteers, touristic operators, social entrepreneurs. 588	
Expected	Outcomes	 /	 Contribution	 to	MAFEIP:	As far as we know there has been no previous 589	
attempt to integrate the concept of RRI to AHA. This synergy will create a baseline for future 590	
development and the integration of this trend in the research and innovation in the field in a 591	
structured and holistic way with the support of relevant stakeholders	592	
3-1-5-	Maturity	Model	for	Integrated	Care	593	
A	Pavlickova,	D	Henderson	594	
Leading	AG:	B3,	Action	Area	7	595	
Rationale:	Scaling up of EIP on AHA good practices in integrated care to EU regions is essential to 596	
reduce health, gender and social inequities in Europe.   597	
General	objectives:	The B3 AG has developed  the B3 Maturity Model to assist  regions with their 598	
efforts to deploy integrated care in Europe in order (i) to reveal strengths and weaknesses of 599	
European regions, (ii) to match those with similar problems and environments to work together and 600	
(iii) to help regions to scale up their activities. 601	
Specific	objectives	602	
1. To share learning and expertise gained during  development of the B3 Maturity Model 	603	
2. To adjust the Maturity Model to address challenges of ageing in Europe such as adherence, 604	
frailty, falls prevention and assisted living solutions.	605	
3. To develop self-assessment tool(s) to assess the readiness of regions with implementation of 606	
solutions for AHA.	607	
4. To test and validate the Maturity Model as a tool for  supporting scaling up and replication of 608	
innovative solutions; and facilitating  knowledge transfer and exchange of good practices in 609	
Europe.	610	
Contribution	to	the	Scaling	Up	Strategy	of	the	EIP	on	AHA:	Aiming to conduct self-assessment in 611	
8 regions, with twinning and coaching activities facilitated by B3 regions.		612	
Expected	Outcomes	/	Contribution	to	MAFEIP		613	
1- Impact on QOL: Scaling up of effective integrated care will improve the quality of care, health 614	
and wellbeing for citizens. 615	
2- Impact on Sustainability of Health and Care Systems: Positioning of European regions in terms 616	
of strengths and weaknesses will inform national, regional and local authorities about their 617	
“future direction of travel” – quick and systematic identification of areas that need an attention 618	
to achieve improvement in AHA solutions. 619	
3- Impact on Economic, Growth and Jobs: Integration of health and care will lead to new roles 620	
and competencies for the workforce, and will generate opportunities for growth through scaling 621	
up of effective models of care / solutions.	622	
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3-2-	Cross-cutting	synergies	focussed	on	an	Action	Group	623	
3-2-1-	Falls	prevention	and	injuries:	a	grand	societal	challenge	624	
P	 Eklund,	 I	 O'Byrne	 Maguire,	 A	 Murray,	 H	 Blain,	 R	 Roller-Wirnsberger,	 L	 Rodriguez-Manas,	 M	625	
Vollenbroek,	A	Teixeira,	N	Guldemond,	A	Catalá,	A	Méndez	Zorrilla,	R	van	de	Bilt,	C	Alonso-Bouzon	626	
Leading	AG:	A2	627	
Rationale: Falls represent a major cause of burden and death in older adults (21).	Approximately 628	
30% of falls result in an injury that requires medical attention, with fractures occurring in 629	
approximately 5%, hip fractures in 1% (22-25) and falls-related injuries account for over 5% 630	
medical expenditures for persons over 65 years. Falls are the third leading cause of years lived with 631	
disability. 632	
General	objectives: Scale up a falls prevention and injuries initiative from local pilot studies to a 633	
practical and feasible pan-European programme including all stakeholders.	634	
Specific	objectives	635	
1- Enable macro-, meso- and micro- level analysis including governance and policy-making based 636	
screening, prevention, rehabilitation and monitoring, and an integration with Silver Economy, 637	
and related to WHO's consultation on Global Strategy and Action Plan on Ageing and Health. 638	
2- Engage regional and municipal levels in fall prevention campaigns, thereby enabling and 639	
promoting early frailty and fall risk assessment, and identifying frail and faller profiles. 640	
3- Anticipate and identify the data analytic scope for health outcomes studies in order to utilize 641	
the infrastructure and support the widest possible variety of health and social studies, including 642	
support for further methods and care services developments related to frailty and fall injury 643	
intervention and prevention. 644	
4- Raise awareness and promote behavioural change among citizens in prevention of frailty and 645	
fall injuries including post-operative interventions. 646	
5- Understanding falls-risk-increasing drugs and frailty. 647	
6- Provision of specific smart home and smart building oriented ICT solutions viewed from a 648	
socio-economic Key Performance Index perspective. 649	
Contribution	 to	 the	 Scaling	 Up	 Strategy	 of	 the	 EIP	 on	 AHA:	 How	 many	 regions:	 Five to ten 650	
demonstrators regions are proposed, including Austria/Steiermark, Finland, France/Languedoc-651	
Roussillon, Ireland, Scotland, Spain (Region of Madrid-Getafe University Hospital and Basque 652	
country). Austria, Finland and France have agreed. Discussions are ongoing with others. 653	
Expected	 Outcomes	 /	 Contribution	 to	MAFEIP:	Scaling-up of good practices with an extended 654	
MAFEIP monitoring framework (2, 3) including socio-economic and macro-economic aspects.	655	
1- Impact on QOL: Fall risk assessment is often embedded into a broader scope of geriatric 656	
assessment, e.g. including cognitive and non-cognitive aspects of dementia, activities of daily 657	
life (ADL), QOL, depression and nutrition. EQ5D is often used but it is not sufficient for a 658	
broader scope of assessment. Finer granularity is needed. 659	
2- Impact on Sustainability of Health and Care Systems: Pathways and care processes are 660	
important ingredients in sustainability. This process sustainability is discussed within the AG. 661	
3- Impact on Economic, Growth and Jobs: The AG is discussing the whole ecosystem, from both 662	
topdown and bottom up approaches. 663	
3-2-2-		Impact	of	Community-based	Program	on	Frailty	Prevention	and	frailty	Mitigation	664	
(ICP	–	FPM)	665	
G	Liotta,	A	Cano,		R	Caoimh,	G	Iaccarino,	M	Illario,	MC	Inzerilli,	M	Maggio,	E	Menditto,	W	Molloy,	666	
C	Paul,	F	Orfila,	R	Roller-Winsberger,		M	Vollenbroek,	L	Rodriguez-Manas	667	
Leading	AG:	A3	668	
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Rationale:	Prevention, screening, early identification and diagnosis of frailty and functional decline 669	
are closely related with integrated care of chronic diseases. They operate primarily in the 670	
community. They require integration of health (primary, secondary) and social care to deliver 671	
screening, targeted assessment (e.g. Comprehensive Geriatric Assessment) and evidence-based, 672	
cost effective and tailored interventions (26-29). Frail subjects  require a comprehensive approach 673	
to prevent disability, recurrent hospitalizations, institutionalization and related heath-social care 674	
costs (26, 30, 31). Interventions must integrate health care and a supportive social environment for 675	
the patient and caregiver (32, 33). Women may be at higher rates of physical and cognitive frailty 676	
and interventions must be gender and cultural sensitive.  677	
General	Objective: (i) To set up a public health approach to prevent, identify and manage frailty in 678	
community dwelling older adults, to be validated in different EU member states, (ii) to develop and 679	
test simple screening strategies to identify those at risk (pre-frail) and those who are frail for triage 680	
to further assessment and (iii) to identify the causes that can be targeted to prevent, delay or 681	
postpone further decline. 682	
Specific	objectives	 	683	
1- To identify effective and sustainable prevention strategies focusing on subjects at risk of frailty 684	
across the nutritional, cognitive, socioeconomic, functional and physical domains. 685	
2- To join systematic frailty assessment with good practices in frailty management counteracting 686	
social isolation, and improving nutrition, adherence to therapy and prevention of falls. 687	
3- To integrate social and health care interventions at primary care level. 688	
4- To promote health care integration at primary and secondary levels. 689	
5- To assess the impact of this public health model to manage frailty in the community in terms of 690	
cost effectiveness, use of health services, acceptance by citizens and patients’ QOL. 691	
6- To exploit existing ICT supported assessment and intervention tools.  692	
7- To describe each individual’s caregiver network’s weaknesses, strengths and implement 693	
strategies to maintain, supplement and improve this network.  694	
Contribution	to	the	Scaling	Up	Strategy	of	the	EIP	on	AHA:	The proposal include projects already 695	
developed in six European countries and is going to include organization based in two more 696	
countries. Objective of the proposal is to represent all the European Regions	697	
Expected	Outcomes	/	Contribution	to	MAFEIP			698	
1-  Impact on Quality of Life: Community-based programs should reduce mortality, 699	
hospitalization and institutionalization rate so that they can improve the elderly QOL. 700	
2- Impact on Sustainability of Health and Care Systems: the proposal will assesses the capacity of 701	
different intervention aimed to  strengthen  community-based health and social care programs 702	
to reduce the work load on hospitals and residential Long Term Care services that are much 703	
more expensive. 704	
3- Impact on Economic, Growth and Jobs: strengthening community-based services needs an 705	
increase of dedicated personnel with potential benefit for the employment levels.	706	
3-2-3-	Multimorbidity	of	chronic	respiratory	diseases	in	old	age	adults:	an	under-recognised	707	
societal	problem	(B3)	708	
J	Bousquet,	M	Bewick,	P	Hellings,	 J	Ankri,	A	Bedbrook,	G	 Iacarino,	P	Kardas,	A	Mair,	 J	Malva,	M	709	
Nogues,	A	Prados-Torres,	L	Rodriguez-Manas,	O	VandenPlas,	B	Vellas,	others	710	
Leading	AG:	B3,	Action	Area	5	711	
Rationale: Chronic Respiratory Diseases (CRD) are major chronic diseases. Some are occurring 712	
early in life (e.g. asthma-rhinitis) and persist throughout life (34, 35). COPD is associated with 713	
frailty in old age adults (multimorbidity, polymedication). CRDs are intertwined with ageing and 714	
negatively impact AHA. Prevention and control of CRD in the ageing population is vital. 715	
Integrated care pathways have been set for CRDs ( AIRWAYS ICPs) in the B3 AG(36-38). 716	
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General	objectives: To better understand, prevent, detect and manage CRDs in old age people, and 717	
to assess their socio-economic and health services utilization impact. Simple ICT tools allowing 718	
individualised medication should be developed. To raise the awareness of the role of CRDs in 719	
elderly, and advocate for a European strategy, in order to support scaling up of regional 720	
interventions. A stepwise action plan is proposed including scientific societies and patient’s 721	
organisations involvement. 722	
Specific	objectives		723	
1- Promotion of AHA: Fit at work with rhinitis: Rhinitis impacts work productivity more than 724	
diabetes, hypertension or asthma. In Europe, work productivity costs due to rhinitis are over 30 725	
B€ yearly. The control of rhinitis by treatment improves work productivity (39). This project 726	
includes care pathways and should be a pilot for other common chronic diseases. 727	
2- Ageing well with rare paediatric diseases (e.g. cystic fibrosis (CF) or bronchopulmonary 728	
dysplasia): The transition between paediatrics, adult medicine and geriatrics is key for AHA in 729	
this severe genetic disease. The model of CF can be deployed to other rare diseases (40). 730	
3- Understanding, promoting health and controlling CRDs across the life cycle for AHA (35) 731	
following the Polish (10, 41) and Cyprus priorities of the EU Council (42). 732	
4- Understanding CRDs in old age people: Care pathways for airway diseases (rhinitis, asthma 733	
and COPD) and their multimorbidities in old age people need to identify prioritized questions 734	
and use ICT tools (43, 44). Public health initiatives to identify those early when presenting in a 735	
pharmacy to purchase treatment. 736	
5- Multimorbidity in CRDs. To describe the clinical profile of patients with CRDs, the patterns 737	
of multimorbidity, and health services use of this groups of patients based on the EpiChron 738	
cohort study (1.3M inhabitants). 739	
6- Integrated care pathways for rhinitis across the life cycle and remote monitoring with a 740	
specific focus on old age adults (43, 44). 741	
7- Interactions between chronic respiratory diseases and frailty 742	
8- Polymedication: In CRDs, and particularly in COPD, patient adherence is a far from perfect. 743	
Most often, patients discontinue their treatment very soon after its initiation. Polymedication has 744	
profound medical and economical consequences. 745	
9- Societal problems in CRDs will be initially tackled with CARSAT (Caisse d’Assurance 746	
Retraite et Santé au Travail, Social Security, France) (17) and scaled up to EU regions using the 747	
ICT tool on AHA (45-47). 748	
10- Scaling up strategy, education, coaching and training (EUFOREA). 749	
Contribution	to	the	Scaling	Up	Strategy	of	the	EIP	on	AHA:	AIRWAYS ICPs is currently deployed 750	
in 25 EU countries with national coordinations.	751	
Expected	Outcomes	/	Contribution	to	MAFEIP	752	
1-  Impact on QOL: All CRDs impact severely QOL across the life cycle. AIRWAYS ICPs is 753	
likely to have a major impact in old age adults. 754	
2- Impact on Sustainability of Health and Care Systems: Novel care pathways including self-care, 755	
health and social carers that are patient-centered are required and represent one of the major 756	
objectives of AIRWAYS ICPs. Better knowledge of the patterns of multimorbidity in CRDs 757	
and the health care use characteristics. 758	
3- Impact on Economic, Growth and Jobs: Fit at work with rhinitis will have a major impact on 759	
economy.	760	
 761	
4-	Embedding	synergies	in	EIP	on	AHA	Reference	Sites	762	 	763	
Synergies have been built among EIP on AHA Reference Sites as illustrative examples of 764	
comprehensive, innovation-based approaches to active and healthy ageing. Reference Sites of the 765	
EIP on AHA are coalitions of regions, cities, integrated hospitals or care organisations that are able 766	
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to show concrete impact of innovative practices, which could be transferred to other European 767	
contexts. A total of 32 Reference Sites have been awarded with this recognition. 768	
 769	
In this context, Reference Sites across European Regions, conscious of the need for synergies and 770	
collaborative approach to addressing health and care challenges of an ageing population, expressed 771	
the common will to establish a Collaborative Network to facilitate joint reflection and action in 772	
sharing and transferring best practice in the development and scaling up of health and care 773	
strategies, policies and service delivery models. It constitutes an excellent example of synergies 774	
building. 775	
 776	
The interregional Reference Site Collaborative Network (RSCN) is comprised of References Sites 777	
recognised by the Commission as well as Regions intending applying for Reference Site status 778	
(candidate Reference Sites). Its main goal is to improve health and care through an active 779	
cooperation with each other, contributing to the general debate with the EU institutions, in order to 780	
optimise the possibilities for sharing a strong, sustainable health and care system for all, while 781	
respecting the different competences and responsibilities in the direct organisation of the health and 782	
care services of the Member States and Regions. In the following table, the RSCN main objectives 783	
are listed: 784	
 785	
Table: Main Objectives 786	
 787	
• Support Reference Sites to learn from each other through twinning events and sharing 788	
information on best practice.  789	
 790	
• Support and co-ordinate Reference Sites in working with each other on joint projects, 791	
funded through Reference Sites internal arrangements and through European funds.  792	
 793	
• Communicate with and react to EU policy developments from Reference Site perspective.  794	
	795	
5-	Support	for	the	EIP	on	AHA	Scaling	up	strategy	 796	
4-1-	EIP	on	AHA	overall	scaling	up	strategy	797	
The Scaling Up Strategy will follow the 5-step approach that has been proposed by the EIP on 798	
AHA and that has already been applied to AIRWAYS ICPs ((https://ec.europa.eu/research/innovation-799	
union/pdf/active-healthy-ageing/scaling_up_strategy.pdf, Bousquet et al, submitted).  800	
An up-scaling strategy is multidimensional where accurate, appropriate and complete execution of 801	
each step is necessary to enable rigorous and systematic fulfilment of subsequent steps in the up-802	
scaling process. As an example, up-scaling the IKINÄ (THL National Falls Prevention Initiative) 803	
guideline for fall prevention by THL (Terveyden ja Hyvinvoinnin Laitos, National Institute for 804	
Health and Welfare, Finland) in Finland (48), may be proposed. WHO's ExpandNet guides (49) to 805	
up-scaling may provide potential additions to the EIP on AHA's Scaling-up Strategy.  806	
The dissemination was proposed to be carried out using the same model as previous B3 AG and/or 807	
AIRWAYS ICPs meetings (35, 38, 42, 45-47, 50-54). 808	
4-2-	Proposal	for	scaling	up	strategy	of	the	AG	synergies	809	
The currently proposed synergies are flexible and should be updated with ongoing or new projects. 810	
New synergies should also be proposed and embedded in a flexible but transparent and structured 811	
manner. It is important that all stakeholders of current synergies and new proposals are well versed 812	
in information and process structures relating to the Scaling-up Strategy and other required 813	
upscaling models adopted (Table 5).   814	
 815	
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Table	5:	Proposal	for	general	rules	for	submitting	new	synergies	activities	816	
 817	
1-	Eligibility	for	submitting	a	proposal	818	
o Only	 a	 member	 of	 the	 EIP	 on	 AHA	 (reference	 site	 or	 commitment	 for	 action	 or	 AG)	 can	 make	 a	819	
proposal.	820	
o In	addition,	the	proposal	leader	should	be	a	member	of	one	of	the	Action	Groups	and	have	the	written	821	
agreement	of	the	AG	coordinator/coordination	team.	822	
o A	review	of	all	requests	will	be	made	at	the	end	of	2016	to	optimize	the	process	for	2017.		823	
o Non-members	of	the	EIP	on	AHA:	only	open	after	January	2017	EXCEPT	if	an	AG	coordinator	indicates	824	
that	the	applicant	is	highly	relevant	for	the	synergy.	825	
2-	New	proposals	should	be:		826	
• Capable	of	integrating	within	a	current	synergy		827	
• OR	new	topic	which	was	not	included	but	considered	after	the	review	of	the	current	synergies.	828	
3-	Only	proposals	submitted	using	the	template	approved	by	the	TF	will	be	considered.		829	
5-	Monitoring	of	activities	carried	out	within	the	synergies	830	
	 5-1-	MAFEIP	831	
Monitoring the activities carried out within the EIP on AHA needs a flexible and consistent 832	
approach to estimate health and economic impacts across interventions and commitments. A 833	
generic and flexible web-based monitoring and assessment tool was developed. The MAFEIP tool 834	
estimates health and economic outcomes in terms of incremental changes in Quality Adjusted Life 835	
Years (QALYs) as well as health and social care utilisation. The MAFEIP-tool can provide an early 836	
assessment of the likelihood that interventions will achieve the anticipated impact, and also to 837	
identify what drives interventions' effectiveness or efficiency to guide further refinement, design 838	
upgrades and evaluation (2, 3). 839	
	 5-2-		AHA	operative	questionnaire	840	
A core operational definition of AHA is needed to conduct comparisons (55). A conceptual AHA 841	
framework proposed by the EIP on AHA Reference Site Collaborative Network includes several 842	
items such as functioning (individual capability and underlying body syste (RSCN)ms), well-being, 843	
activities and participation, and diseases (including non-communicable diseases, frailty, mental and 844	
oral health disorders) (45, 46). The instruments proposed include core and optional 845	
domains/instruments depending on the needs and the questions (47). A major common domain is 846	
function as measured by the World Health Organization Disability Assessment Schedule 2.0 847	
(WHODAS 2.0) that can be used across all diseases and healthy individuals. It covers many of the 848	
AHA dimensions proposed by the RSCN. However, WHODAS-2.0 does not include all 849	
dimensions proposed for AHA assessment. The second common domain is Health-Related QOL 850	
(HRQL). EQ-5D is one of the QALY measurements and The AHA questionnaire is therefore 851	
interoperable with MAFEIP. The instrument is translated and culturally validated for most EU 852	
countries and will be digitalized in the first quarter of 2016. A report of the AHA questionnaire in 853	
the form of a spider diagram will facilitate usual comparisons across individuals and groups of 854	
interest (55). 855	
	 5-3-	Other	tools	856	
Assessment scales, as information entities, are not often equipped with rigorous typing of data. 857	
This disables the gap between logic and guidelines not only in geriatric assessment (56)  but also 858	
within municipal and regional decision-making in older person care. Logic is, on the one hand, a 859	
carrier of information, and, on the other hand, it includes a mechanism for rigorous logical 860	
inference which underlies decision-making. Gerontological conditions and circumstances are about 861	
information and knowledge, and gerontological data can be properly typed to open up possibilities 862	
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e.g. for comparative studies and development of regional and national repositories involving 863	
gerontological data and information (57). 864	
The information structure representation of nomenclatures and classifications is also important. 865	
WHO classifications are logically lative (58). The reference classifications ICD (International 866	
Classification of Diseases) and ICF (International Classification of Functioning, Disability and 867	
Health) then appear in structured relation with each other. Similar transformations can be made for 868	
the derived and related classifications ICPC-2, ICECI, ISO9999, ATC/DDD and ICNP (59). 869	
These information entities are inherently multivalent, and classifications like the ICF explicitly 870	
recognizes this multivalence through introduction of its generic scale. This in turn requires to 871	
formally manage many-valuedness and uncertainty in a logical setting (49). 872	
Conclusion		873	
AHA requires a multidimensional and multidisciplinary approach to allow people from multiple 874	
backgrounds to work together sharing a common language. The experience of different 875	
stakeholders working on a collaborative way producing concrete results in the different Action 876	
Groups sets a promising ground for the difficult challenge of scaling up good practices at European 877	
level. 878	
The added value of working together requires identifying synergies not only between different 879	
good practices but also between different Action Groups’ results. To yield actual benefits they have 880	
to be developed in concrete action plans that explain the rationale for the synergy, the participants, 881	
the objectives and a concrete plan with sprints.   882	
EIP AHA implementation can manage a limited number of synergy actions. To select them a 883	
flexible but structured process, with a transparent evaluation methodology had to be used. The 884	
success of the first call with nine proposals submitted and evaluated supports the viability of the 885	
approach chosen. Eight were selected. 886	
New stakeholders have to join and new proposals implemented. To make sure the added value of 887	
the whole process, Actions have to be assessed according to their estimated health and economic 888	
outcomes as well as health and social care utilisation using MAFEIP and other tools. 889	
	 	890	
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